Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines

Anticancer Research

Volumn 28, Issue 4 B, 2008, Pages 2147-2154

  Murayama, Takashi ^a   Kawasoe, Yasuomi ^a   Yamashita, Yoshitaka ^a   Ueno, Yoshinori ^a   Minami, Syusaku ^a   Yokouchi, Masahiro ^a,b   Komiya, Setsuro ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Apoptosis; Bisphosphonate; Osteosarcoma; Synergism

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; DOXORUBICIN; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAP1 PROTEIN; RAS PROTEIN; RISEDRONIC ACID; VINCRISTINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DNA FRAGMENTATION; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MOUSE; NICK END LABELING; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; OSTEOSARCOMA; PRENYLATION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; CARBOPLATIN; CELL LINE, TUMOR; DOXORUBICIN; DRUG SYNERGISM; ETIDRONIC ACID; ETOPOSIDE; GTP-BINDING PROTEINS; HUMANS; OSTEOSARCOMA; PRENYLATION; VINCRISTINE;

EID: 49049100911     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Dorfman HD and Czerniak B: Bone cancers. Cancer 75: 203-210, 1995.
2. Whelan JS: Osteosarcoma. Eur J Cancer 33: 1611-1618, discussion 1618-1619, 1997.
3. Jaffe N, Patel SR, and Benjamin RS: Chemotherapy in osteosarcoma. Basis for application and antagonism to implementation; early controversies surrounding its implementation. Hematol Oncol Clin North Am 9: 825-840, 1995.
4. Ferrari S, Bacci G, Picci P, Mercuri M, Briccoli A, Pinto D, Gasbarrini A, Tienghi A and Brach del Prever A: Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 8: 765-771, 1997.
5. Bramwell VH: The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol 24: 561-571, 1997.
6. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J and Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88: 2961-2978, 2000.
7. Rodan GA: Bone mass homeostasis and bisphosphonate action. Bone 20: 1-4, 1997.
8. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E and Rodan GA: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88: 2095-2105, 1991.
9. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR and Boyce BF: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487, 1995.
10. Lowik CW, van der Pluijm G, van der Wee-Pals LJ, van Treslong-De Groot HB and Bijvoet OL: Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 3: 185-192, 1988.
11. Hughes DE, MacDonald BR, Russell RG and Gowen M: Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83: 1930-1935, 1989.
12. Benford HL, Frith JC, Auriola S, Monkkonen J and Rogers MJ: Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 56: 131-140, 1999.
13. Frith JC, Monkkonen J, Blackburn GM, Russell RG and Rogers MJ: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12: 1358-1367, 1997.
14. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A and Rogers MJ: Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15: 1467-1476, 2000.
15. Luckman SP, Hughes DE, Coxon FP, Graham R, Russell G and Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589, 1998.
16. Zhang FL and Casey PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65: 241-269, 1996.
17. Coukell AJ and Markham A: Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging 12: 149-168, 1998.
18. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD, Yunus F, Bell R, Body J, Quebe-Fehling E and Seaman J: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19: 558-567, 2001.
19. Shipman CM, Croucher PI, Russell RG, Helfrich MH and Rogers MJ: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58: 5294-5297, 1998.
20. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P and Venuta S: Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14: 841-844, 2000.
21. Fromigue O, Lagneaux L and Body JJ: Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 15: 2211-2221, 2000.
22. Senaratne SG, Pirianov G, Mansi JL, Arnett TR and Colston KW: Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82: 1459-1468, 2000.
23. Lee MV, Fong EM, Singer FR and Guenette RS: Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res 61: 2602-2608, 2001.
24. Kuroda J, Kimura S, Segawa H, Kobayashi Y, Yoshikawa T, Urasaki Y, Ueda T, Enjo F, Tokuda H, Ottmann OG and Maekawa T: The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate. Blood 102: 2229-2235, 2003.
25. Magnetto S, Boissier S, Delmas PD and Clezardin P: Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. Int J Cancer 83: 263-269, 1999.
26. Hiraga T, Williams PJ, Mundy GR and Yoneda T: The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Res 61: 4418-4424, 2001.
27. Sonnemann J, Eckervogt V, Truckenbrod B, Boos J, Winkelmann W and van Valen F: The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro. Anticancer Drugs 12: 459-465, 2001.
28. Mackie PS, Fisher JL, Zhou H and Choong PF: Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line. Br J Cancer 84: 951-958, 2001.
29. Evdokiou A, Labrinidis A, Bouralexis S, Hay S and Findlay DM: Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 33: 216-228, 2003.
30. Kubista B, Trieb K, Sevelda F, Toma C, Arrich F, Heffeter P, Elbling L, Sutterluty H, Scotlandi K, Kotz R, Micksche M and Berger W: Anticancer effects of zoledronic acid against human osteosarcoma cells. J Orthop Res 6: 1145-1152, 2006.
31. Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F and Redini F: Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone 37: 74-86, 2005.
32. Horie N, Murata H, Kimura S, Takeshita H, Sakabe T, Matsui T, Maekawa T, Kubo T and Fushiki S: Combined effects of a third-generation bisphosphonate, zoledronic acid with other anticancer agents against murine osteosarcoma. Br J Cancer 96: 255-261, 2007.
33. Kubo T, Shimose S, Matsuo S, Tanaka K, Yasunaga Y, Sakaki A and Ochi M: Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells. J Orthop Res 24: 1138-1144, 2006.
34. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
35. Shipman CM, Rogers MJ, Apperley JF, Russell RG and Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 98: 665-672, 1997.
36. Sanders JM, Gomez AO, Mao J, Meints GA, Van Brussel EM, Burzynska A, Kafarski P, Gonzales-Pacanowska D and Oldfield E: 3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates. J MED CHEM 46: 5171-5183, 2003.
37. Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, Triozzi P and Selander KS: Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clinical Cancer Res 12: 2862-2868, 2006.
38. Whyte MP, Wenkert D, Clements KL, McAlister WH and Mumm S: Bisphosphonate-induced osteopetrosis. N Engl J Med 349: 457-463, 2003.